MétaCan
Menu
Back to cohort
Record W2059273370 · doi:10.1016/j.ymthe.2006.08.730

654. Targeting Adenoviral Vectors for Use in Breast Cancer Gene Therapy

2006· article· en· W2059273370 on OpenAlexaff
AlanD. DeSilva, LeonardI. Wiebe, Chang-Xin Shi, MabroukM. Elgadi, Gianluca Bossi, MaryM. Hitt

Bibliographic record

VenueMolecular Therapy · 2006
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicVirus-based gene therapy research
Canadian institutionsMcMaster UniversityUniversity of Alberta
Fundersnot available
KeywordsThymidine kinaseGenetic enhancementBreast cancerGanciclovirViral vectorCancer researchSuicide geneGene deliveryIn vivoCancer cellCancerBiologyHerpes simplex virusMolecular biologyMedicineVirologyVirusGeneHuman cytomegalovirusRecombinant DNA

Abstract

fetched live from OpenAlex

The results of many cancer gene therapy clinical trials to date suggest that improvements must be made to increase gene delivery, expression levels, and/or potency of the genes in order to induce tumour regression. However, increasing any of these parameters will require additional safeguards to protect surrounding normal cells. Our goal is to develop adenoviral vector systems that target tumour cells transcriptionally (using various tumour- and tissue- specific promoters) as well as transductionally (by modifying the viral fiber protein to enhance binding to receptors on the tumour cell surface). We have isolated a novel promoter from the mammaglobin (MGB) gene that displays over ten-fold increase in expression levels in breast cancer cells relative to normal non-tumour cells (Shi, et al., 2004, Mol. Ther., 10:758–767; Shi, et al., 2006, J. Gene Med, in press). We have since developed a breast cancer targeted adenoviral (Ad) vector encoding the “suicide gene” herpes simplex virus (HSV)-1 thymidine kinase (TK) under the control of the MGB promoter (AdMGBTK). HSV-TK was chosen for this study because, in combination with nucleoside analogs, it has potential not only as a therapeutic, but also as an agent for non-invasive imaging of gene transfer in vivo. AdMGBTK, in combination with the prodrug ganciclovir (GCV), induces breast cancer-specific killing at levels comparable to a universal cytomegalovirus (CMV) TK vector. Combination with a radiolabeled TK substrate allows Positron Emission Tomography (PET) imaging in vivo, which has never been performed on breast cancer targeted vectors. In addition, we have engineered a modified-fiber virus to contain the ligand-binding domain of heregulin-α (HRG-α) within the fiber protein of Ad. HRG-α is a ligand for ErbB3 and ErbB4 receptors, both of which are over-expressed in many cancer types, including breast cancer. This modified-fiber virus demonstrated enhanced infection of tumour cells bearing ErbB3 and ErbB4. Generation of a vector expressing TK under the control of the MGB promoter and encapsidated within an HRG-modified fiber virus is in progress. This combination of transcriptional and translational targeting is expected to produce a highly specific breast cancer-targeted adenoviral vector which has potential as a clinical therapeutic.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.293
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2006
Admission routes1
Has abstractyes

Explore more

Same venueMolecular TherapySame topicVirus-based gene therapy researchFrench-language works237,207